Mallika L. Mendu
Brigham and Women's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mallika L. Mendu.
Journal of Clinical Oncology | 2013
Ayal A. Aizer; Ming-Hui Chen; Ellen P. McCarthy; Mallika L. Mendu; Sophia Koo; Tyler J. Wilhite; Powell L. Graham; Toni K. Choueiri; Karen E. Hoffman; Neil E. Martin; Jim C. Hu; Paul L. Nguyen
PURPOSE To examine the impact of marital status on stage at diagnosis, use of definitive therapy, and cancer-specific mortality among each of the 10 leading causes of cancer-related death in the United States. METHODS We used the Surveillance, Epidemiology and End Results program to identify 1,260,898 patients diagnosed in 2004 through 2008 with lung, colorectal, breast, pancreatic, prostate, liver/intrahepatic bile duct, non-Hodgkin lymphoma, head/neck, ovarian, or esophageal cancer. We used multivariable logistic and Cox regression to analyze the 734,889 patients who had clinical and follow-up information available. RESULTS Married patients were less likely to present with metastatic disease (adjusted odds ratio [OR], 0.83; 95% CI, 0.82 to 0.84; P < .001), more likely to receive definitive therapy (adjusted OR, 1.53; 95% CI, 1.51 to 1.56; P < .001), and less likely to die as a result of their cancer after adjusting for demographics, stage, and treatment (adjusted hazard ratio, 0.80; 95% CI, 0.79 to 0.81; P < .001) than unmarried patients. These associations remained significant when each individual cancer was analyzed (P < .05 for all end points for each malignancy). The benefit associated with marriage was greater in males than females for all outcome measures analyzed (P < .001 in all cases). For prostate, breast, colorectal, esophageal, and head/neck cancers, the survival benefit associated with marriage was larger than the published survival benefit of chemotherapy. CONCLUSION Even after adjusting for known confounders, unmarried patients are at significantly higher risk of presentation with metastatic cancer, undertreatment, and death resulting from their cancer. This study highlights the potentially significant impact that social support can have on cancer detection, treatment, and survival.
JAMA Internal Medicine | 2009
Mallika L. Mendu; Gail McAvay; Rachel Lampert; Jonathan Stoehr; Mary E. Tinetti
BACKGROUND Syncopal episodes are common among older adults; etiologies range from benign to life threatening. We determined the frequency, yield, and costs of tests obtained to evaluate older persons with syncope. We also calculated the cost per test yield and determined whether the San Francisco syncope rule (SFSR) improved test yield. METHODS Review of 2106 consecutive patients 65 years or older admitted following a syncopal episode. RESULTS Electrocardiograms (in 99% of admissions), telemetry (in 95%), cardiac enzyme tests (in 95%), and head computed tomographic (CT) scans (in 63%) were the most frequently obtained tests. Results from cardiac enzymes tests, CT scans, echocardiography, carotid ultrasonography, and electroencephalography all affected diagnosis or management in less than 5% of cases and helped determine the etiology of syncope less than 2% of the time. Postural blood pressure (BP) recording, performed in only 38% of episodes, had the highest yield with respect to affecting diagnosis (18%-26%) or management (25%-30%) and determining etiology of the syncopal episode (15%-21%). The cost per test affecting diagnosis or management was highest for electroencephalography (
Journal of Clinical Oncology | 2014
Ayal A. Aizer; Benjamin P. Falit; Mallika L. Mendu; Ming-Hui Chen; Toni K. Choueiri; Karen E. Hoffman; Jim C. Hu; Neil E. Martin; Quoc-Dien Trinh; Brian M. Alexander; Paul L. Nguyen
32 973), CT scans (
Chest | 2011
Sam Zager; Mallika L. Mendu; Domingo Chang; Heidi S. Bazick; Andrea Braun; Fiona K. Gibbons; Kenneth B. Christopher
24 881), and cardiac enzymes test (
Critical Care Medicine | 2015
Clare Horkan; Steven W. Purtle; Mallika L. Mendu; Takuhiro Moromizato; Fiona K. Gibbons; Kenneth B. Christopher
22 397) and lowest for postural BP recording (
Clinical Journal of The American Society of Nephrology | 2014
Mallika L. Mendu; Louise I. Schneider; Ayal A. Aizer; Karandeep Singh; David E. Leaf; Thomas H. Lee; Sushrut S. Waikar
17-
Critical Care Medicine | 2012
Mallika L. Mendu; Sam Zager; Fiona K. Gibbons; Kenneth B. Christopher
20). The yields and costs for cardiac tests were better among patients meeting, vs those not meeting, the SFSR. For example, the cost per cardiac enzymes test affecting diagnosis or management was
Clinical Journal of The American Society of Nephrology | 2017
Mallika L. Mendu; George Ciociolo; Sarah R. McLaughlin; Dionne A. Graham; Roya Ghazinouri; Siddharth Parmar; Alissa Grossier; Rebecca Rosen; Karl Laskowski; Leonardo V. Riella; Emily Robinson; David M. Charytan; Joseph V. Bonventre; Jeffrey O. Greenberg; Sushrut S. Waikar
10 331 in those meeting, vs
Journal of Critical Care | 2014
Caitlin K. McKane; Melina E. Marmarelis; Mallika L. Mendu; Takuhiro Moromizato; Fiona K. Gibbons; Kenneth B. Christopher
111 518 in those not meeting, the SFSR. CONCLUSIONS Many unnecessary tests are obtained to evaluate syncope. Selecting tests based on history and examination and prioritizing less expensive and higher yield tests would ensure a more informed and cost-effective approach to evaluating older patients with syncope.
Journal of Critical Care | 2013
Mallika L. Mendu; Sam Zager; Takuhiro Moromizato; Caitlin K. McKane; Fiona K. Gibbons; Kenneth B. Christopher
PURPOSE The Patient Protection and Affordable Care Act (ACA) will likely improve insurance coverage for most young adults, but subsets of young adults in the United States will face significant premium increases in the individual market. We examined the association between insurance status and cancer-specific outcomes among young adults. METHODS We used the SEER program to identify 39,447 patients age 20 to 40 years diagnosed with a malignant neoplasm between 2007 and 2009. The association between insurance status and stage at presentation, employment of definitive therapy, and all-cause mortality was assessed using multivariable logistic or Cox regression, as appropriate. RESULTS Patients who were uninsured were more likely to be younger, male, nonwhite, and unmarried than patients who were insured and were also more likely to be from regions of lower income, education, and population density (P < .001 in all cases). After adjustment for pertinent confounding variables, an association between insurance coverage and decreased likelihood of presentation with metastatic disease (odds ratio [OR], 0.84; 95% CI, 0.75 to 0.94; P = .003), increased receipt of definitive treatment (OR, 1.95; 95% CI, 1.52 to 2.50; P < .001), and decreased death resulting from any cause (hazard ratio, 0.77; 95% CI, 0.65 to 0.91; P = .002) was noted. CONCLUSION The improved coverage fostered by the ACA may translate into better outcomes among most young adults with cancer. Extra consideration will need to be given to ensure that patients who will face premium increases in the individual market can obtain insurance coverage under the ACA.